Loading…
CDMO manufacturing pharmaceutical intermediates, APIs and specialty chemicals for global pharma and life-sciences companies.
CDMO manufacturing pharmaceutical intermediates, APIs and specialty chemicals for global pharma and life-sciences companies.
In one line: A newer Indian pharma/specialty-chemical CDMO.
Moat: narrow (process know-how, regulatory licence). Regulated manufacturing plants and multi-year CDMO contracts create switching costs for pharma clients.
Headquarters: Hyderabad, India · Employees: 5,051
Size Cohance Lifesciences (COHANCE.NS) is an India Health Care company (Pharmaceuticals: Major) with a market value of $1.75B, the 405th largest of 1,058 India companies the cockpit tracks. Shares closed at ₹433.55 on 6 Nov 2026.
Performance Over six months the shares fell 10.6%, against -10.8% for the median peer and 0.0% for the India market (cap-weighted) — 9th highest of 20 in its peer set.
Growth Revenue grew 41.2% over the last twelve months (peer median +5.0%); the operating margin is 5.8% (peer median 13.1%).
Valuation It trades at 82.6× forward earnings against a peer median of 18.8× (most expensive of 16).
Capital Return on invested capital runs 13.1 points below its cost of capital (15.5% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₹21.4B | ₹22.4B | ₹25.7B | ₹10.4B | ₹13.3B |
| Revenue growth | — | -13% | +148% | -22% | — |
| Gross profit | ₹8.08B | ₹4.85B | ₹8.64B | ₹4.38B | ₹5.87B |
| EBITDA | ₹3.16B | ₹4.15B | ₹8.06B | ₹4.05B | ₹5.84B |
| Net income | ₹1.06B | ₹1.79B | ₹4.87B | ₹3.00B | ₹4.11B |
| Free cash flow | n/a | ₹1.35B | ₹3.31B | ₹3.29B | ₹1.66B |
| Capital expenditure | n/a | ₹2.20B | ₹3.17B | ₹519M | ₹2.86B |
| Total debt | ₹2.08B | ₹4.00B | ₹4.86B | ₹650M | ₹703M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Cohance Lifesciences COHANCE.NS | $1.75B | -11% | +41% | 6% | 82.6× | n/a |
| Neuland Laboratories NEULANDLAB.NS | $2.68B | +14% | +50% | 26% | 54.3× | n/a |
| Divi's Laboratories DIVISLAB.NS | $29.0B | +54% | +16% | 31% | 82.0× | 50.9% |
| Piramal Pharma PPLPHARMA.NS | $3.37B | +30% | +9% | 3% | 159.9× | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | COHANCE.NS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -4.8% | -0.1% | 5th lowest of 21 |
| 6-month return | -10.6% | -10.8% | 9th highest of 20 |
| Distance from 52-week high | -44.4% | -28.4% | 3rd lowest of 21 |
| Revenue growth (TTM) | +41.2% | +5.0% | 2nd highest of 19 |
| Operating margin | 5.8% | 13.1% | 4th lowest of 19 |
| Forward P/E | 82.6× | 18.8× | most expensive of 16 |
| ROIC minus cost of capital | -13.1 pp | +1.4 pp | 3rd lowest of 20 |
| EV / EBITDA | 52.0× | 14.1× | 2nd most expensive of 9 |
| Net debt / EBITDA | -0.8× | -1.4× | 4th most indebted of 9 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Cohance Lifesciences COHANCE.NS | India | $1.75B | -11% | +41% | 6% | 82.6× | n/a | n/a |
| Agios Pharmaceuticals AGIO | United States | $1.76B | +6% | +141% | -467% | n/a | n/a | n/a |
| Beijing Aosaikang Pharmaceutical 002755.SZ | China | $1.76B | -25% | -13% | 12% | 63.3× | 14.7% | -14.0% |
| Zhejiang Wolwo Bio-Pharmaceutical 300357.SZ | China | $1.77B | -11% | +7% | 39% | 27.8× | 19.5% | +10.8% |
| Yifan Pharmaceutical 002019.SZ | China | $1.72B | -14% | -5% | 8% | 27.8× | n/a | n/a |
| PharmaResearch 214450.KS | South Korea | $1.79B | -25% | +34% | 39% | 12.4× | -14.2% | +37.6% |
| Faes Farma FAE.MC | Spain | $1.71B | +5% | +32% | 14% | 17.1× | 3.1% | +9.9% |
| Tsumura & 4540.T | Japan | $1.81B | +2% | +10% | 18% | 10.1× | n/a | n/a |
| SELLAS Life Sciences SLS | United States | $1.70B | +68% | n/a | n/a | n/a | n/a | n/a |
| Eris Lifesciences ERIS.NS | India | $1.82B | -11% | +11% | 26% | 25.7× | 24.7% | +20.9% |
| AstraZeneca Pharma India ASTRAZEN.NS | India | $1.69B | -25% | +31% | 10% | n/a | 49.3% | +23.0% |
| NATCO Pharma NATCOPHARM.NS | India | $1.68B | -30% | -21% | 25% | 18.8× | 15.3% | +19.0% |
| Braveheart Bio BRVE | United States | $1.67B | n/a | n/a | n/a | n/a | n/a | n/a |
| Yantai Dongcheng Biochemicals 002675.SZ | China | $1.67B | +1% | -4% | 15% | 47.5× | 6.7% | -4.3% |
| Guobang Pharma 605507.SS | China | $1.84B | -8% | +3% | 12% | 15.9× | -5.8% | +7.4% |
| Shanghai Shyndec Pharmaceutical 600420.SS | China | $1.67B | -14% | -13% | 6% | 13.2× | -6.0% | -5.6% |
| China National Accord Medicines 000028.SZ | China | $1.85B | -4% | 0% | 2% | 11.1× | -9.4% | +4.2% |
| Consun Pharmaceutical 1681.HK | Hong Kong | $1.65B | +5% | +15% | 35% | 9.2× | -15.1% | +13.5% |
| Pfizer PFIZER.NS | India | $1.87B | -19% | +12% | 34% | 21.5× | 11.2% | +2.4% |
| Shenzhen Hepalink Pharmaceutical 002399.SZ | China | $1.88B | -13% | -6% | 8% | 22.5× | 0.1% | +0.5% |
| Sarepta Therapeutics SRPT | United States | $1.88B | -11% | -20% | -3% | n/a | 11.9% | +32.4% |